CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 93 enrolled
Drug / intervention
bimatoprost 0.01% +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01881126
NCT01881126Phase 4Completed
CompareCT.gov

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Allergan·interventional·Posted Jun 19, 2013·Updated Nov 30, 2015

In Brief

A Phase 4 clinical trial evaluating bimatoprost 0.01%, travatan 0.004%, and 2 other interventions for Glaucoma and Ocular Hypertension. Completed, enrolled 93 participants across 2 sites.

Detailed Summary

This efficacy and safety study will evaluate LUMIGAN® RC/ LUMIGAN® .01 (bimatoprost 0.01%) alone compared to TRAVATAN Z® (travoprost 0.004%) and TIMOLOL MALEATE-EX, 0.5%/TIMOLOL GFS 0.5% (timolol 0.5% ophthalmic gel forming solution) in patients who require IOP lowering therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesCanada
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 19, 2013
Enrollment StartJun 1, 2013
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 13.0 years ago

Interventions

bimatoprost 0.01%drug

Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.

travatan 0.004%drug

Travatan 0.004% administered to both eyes once daily for 12 weeks.

timolol 0.5%drug

Timolol 0.5% administered to both eyes once daily for 12 weeks.

hypromellose 0.3%drug

Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.